Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black.
作者： Nicolás Roberto Robles , Juan Francisco Macias , Julio Herrera
DOI: 10.1016/J.EJIM.2013.12.011
关键词: Cardiology 、 Disease 、 Erythropoiesis 、 Internal medicine 、 Anemia 、 Erythropoietin 、 Medicine 、 Quality of life 、 Heart failure 、 High incidence 、 Intensive care medicine 、 Increased risk
摘要: CHF is a disease of high incidence and prevalence in the elderly. Anemia associated with an increased mortality these patients. Erythropoietin secretion reduced patients due to complexed mechanisms. Although some improvement quality life has been shown when using ESAs it not found any decrement on mortality. Moreover, safety reports suggest risk thromboembolic event. Together drug cost, use cannot be recommended for treatment
elsevier.com
sci-hub.se 参考文章(56)
JR Robert T. Means, Advances in the anemia of chronic disease. International Journal of Hematology. ,vol. 70, pp. 7- 12 ,(1999)
Emerson C. Perin, Choosing a Drug-Eluting Stent: A Comparison Between CYPHER and TAXUS Reviews in Cardiovascular Medicine. ,vol. 6, pp. 13- 21 ,(2005)
Darlington O. Okonko, Agnieszka Grzeslo, Tomasz Witkowski, Amit K.J. Mandal, Robert M. Slater, Michael Roughton, Gabor Foldes, Thomas Thum, Jacek Majda, Waldemar Banasiak, Constantinos G. Missouris, Philip A. Poole-Wilson, Stefan D. Anker, Piotr Ponikowski, Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial Journal of the American College of Cardiology. ,vol. 51, pp. 103- 112 ,(2008) , 10.1016/J.JACC.2007.09.036
Piotr Ponikowski, Stefan D. Anker, Joanna Szachniewicz, Darlington Okonko, Mark Ledwidge, Robert Zymlinski, Enda Ryan, Scott M. Wasserman, Nigel Baker, Dylan Rosser, Stuart D. Rosen, Philip A. Poole-Wilson, Waldemar Banasiak, Andrew J.S. Coats, Ken McDonald, Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial Journal of the American College of Cardiology. ,vol. 49, pp. 753- 762 ,(2007) , 10.1016/J.JACC.2006.11.024
DJ van Veldhuisen, A Palazzuoli, D Kotecha, L Manzano, K Ngo, Jae Walters, M Flather, Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients (Intervention Review) Cochrane Database of Systematic Reviews. ,vol. 2010, pp. 1- 62 ,(2010)
Anatole Besarab, Managing anemia in patients with chronic heart failure: what do we know? Vascular Health and Risk Management. ,vol. 6, pp. 237- 252 ,(2010) , 10.2147/VHRM.S4619
Yi-Da Tang, Stuart D. Katz, The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Failure Reviews. ,vol. 13, pp. 387- 392 ,(2008) , 10.1007/S10741-008-9089-7
Kevin Stefanik, Dennis J. Cotter, Mae Thamer, James Kaufman, Yi Zhang, Epoetin requirements predict mortality in hemodialysis patients American Journal of Kidney Diseases. ,vol. 44, pp. 866- 876 ,(2004) , 10.1053/J.AJKD.2004.08.002
Ana-Silvia Androne, Stuart D. Katz, Lars Lund, John LaManca, Alhakam Hudaihed, Katarzyna Hryniewicz, Donna M. Mancini, Hemodilution Is Common in Patients With Advanced Heart Failure Circulation. ,vol. 107, pp. 226- 229 ,(2003) , 10.1161/01.CIR.0000052623.16194.80
Luís Beck-da-Silva, Diogo Piardi, Stephan Soder, Luís Eduardo Rohde, Antônio Carlos Pereira-Barretto, Denílson de Albuquerque, Edimar Bocchi, Fábio Vilas-Boas, Lídia Zytynzki Moura, Marcelo W. Montera, Salvador Rassi, Nadine Clausell, IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia International Journal of Cardiology. ,vol. 168, pp. 3439- 3442 ,(2013) , 10.1016/J.IJCARD.2013.04.181